Myocarditis and myositis associated with tocilizumab

被引：0

作者：

Ladhari, C. ^{[1
]}

Palassin, P. ^{[1
]}

Le Souder, C. ^{[1
]}

Faillie, J. L. ^{[1
]}

Maria, A. ^{[2
]}

Hillaire-Buys, D. ^{[1
]}

机构：

[1] CHU, Dept Pharmacol Med & Toxicol, Ctr Reg Pharmacovigilance Montpellier, Montpellier, France

[2] CHU, Dept Med Interne, Montpellier, France

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2021年 / 35卷

关键词：

myocarditis; myositis; tocilizumab; pharmacovigilance; adverse drug reactions;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PS-091

引用

页码：135 / 135

页数：1

共 3 条

[1] Tocilizumab in the treatment of myocardial infarction [J].

Carroll, Matthew B. .

MODERN RHEUMATOLOGY, 2018, 28 (05) :733-735

[2] Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis [J].

Savvatis, Konstantinos ;

Mueller, Irene ;

Froehlich, Matthias ;

Pappritz, Kathleen ;

Zietsch, Christin ;

Hamdani, Nazha ;

Grote, Karsten ;

Schieffer, Bernhard ;

Klingel, Karin ;

Van Linthout, Sophie ;

Linke, Wolfgang A. ;

Schultheiss, Heinz-Peter ;

Tschoepe, Carsten .

BASIC RESEARCH IN CARDIOLOGY, 2014, 109 (06)

[3] Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab [J].

Vilaiyuk, Soamarat ;

Lerkvaleekul, Butsabong ;

Soponkanaporn, Sirisucha ;

Setthaudom, Chavachol ;

Buranapraditkun, Supranee .

CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 44 (02) :150-158

← 1 →